Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest Rosiglitazone Stories

2008-09-09 09:00:09

New data analyses presented at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed initial combination therapy with the dipeptidyl peptidase-4 (DPP-4) inhibitor, JANUVIA(TM) (sitagliptin), and metformin provided improvements in blood sugar levels (as measured by A1C(1)) over two years of treatment and was generally well tolerated. Also presented at the meeting was a separate, new pooled analysis of 6,139 patients that showed that JANUVIA was generally...

2008-09-08 09:00:08

Results from two 24-week Phase III studies presented at the 44th European Association for the Study of Diabetes Annual Meeting demonstrated that ONGLYZA(TM) (saxagliptin), an investigational selective inhibitor with extended binding to the dipeptidyl peptidase-4 (DPP-4) enzyme in development by Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN), produced significant reductions across all key measures of glucose control studied (glycosylated hemoglobin level (A1C), fasting...

2008-09-08 06:00:05

ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk , a global healthcare company, presented data from a phase 3 clinical study (LEAD(TM) 4) today at the 44th annual meeting of the European Association for the Study of Diabetes that demonstrated adding the investigational new drug liraglutide, a human GLP-1 analog, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering (HbA1c), weight loss, blood pressure reduction and improvements in...

2008-08-29 15:00:53

A class of oral drugs used to treat type 2 diabetes may increase the risk of heart failure, two Wake Forest University School of Medicine faculty members said. Dr. Sonal Singh and Dr. Curt D. Furberg said in an editorial in the journal Heart that they strongly recommend restrictions in the use of thiazolidinediones -- the class of drugs used to control diabetes by lowering blood sugar -- and question the rationale for leaving rosiglitazone on the market. Rosiglitazone and pioglitazone are...

2008-08-13 15:01:02

A wrongful death suit was filed against GlaxoSmithKline, SmithKline Beecham, and McKesson Corporation in California Superior Court, charging that Avandia, prescribed for Type 2 Diabetes, led to heart attacks, congestive heart failure and other fatal cardiovascular injuries in seven individuals. The suit, brought by Khorrami, Pollard & Abir and Kabateck Brown Kellner, LLP, was filed on behalf of the victims' seven surviving spouses, including Los Angeles, CA, and Costa Mesa, CA,...

2008-07-14 09:00:14

PHILADELPHIA, July 14 /PRNewswire-FirstCall/ -- GlaxoSmithKline announces today that the U.S. Food and Drug Administration (FDA) updated the prescribing information for AVANDIA(R) (rosiglitazone maleate) to include clinical findings from A Diabetes Outcome Progression Trial (ADOPT), a 4- to- 6 year head-to-head study of AVANDIA versus metformin and glyburide monotherapy in recently diagnosed type 2 diabetes patients. The percentage of patients with inadequate glucose control at five years...

a7730d4f1427c495f0c9b66860eaf672
2008-07-02 00:05:00

Speaking before a U.S. advisory panel, Cleveland Clinic cardiologist Steven Nissen said higher standards of testing should be enforced to ensure that new proposed diabetes medicines do not damage patients' hearts. "We have to rule out some level of harm prior to approval," Cleveland Clinic cardiologist Steven Nissen told the panel of experts that advises the Food and Drug Administration. Some experts claim that stricter regulation may require longer clinical testing periods, which could slow...

ae228dfc7bdb3850b37c3f3e02ba3dd91
2008-01-31 10:20:00

Iowa Senator Charles Grassley said yesterday that Dr. Steven M. Haffner, a well-known diabetes expert at the University of Health Science Center in San Antonio, had leaked confidential, unpublished information to GlaxoSmithKline (GSK) that questioned the safety of the company's diabetes drug Avandia.A New York Times report said that Dr. Haffner had faxed the document, a medical journal article he had agreed to read as part of the normal prepublication peer review process for The New England...

2007-08-02 06:16:49

By Barnett, Anthony Allsworth, Josie; Jameson, Kevin; Mann, Rachel Key words: DPP-4 inhibitor - Glitazone - Incretin - Metformin - Type 2 diabetes - Weight gain ABSTRACT Background: Current American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) treatment guidelines recommend metformin (which does not promote weight gain) as the first-line antihyperglycaemic drug for patients with type 2 diabetes. However, when metformin fails, the recommended add-on...

80ec3d4bc48aac4c78c637710e0f358c1
2007-05-23 14:30:00

How does a drug go from blockbuster to bust? How can big safety issues go undetected in medicines taken by millions of people for many years, as happened this week with the diabetes pill Avandia and a few years ago with the painkiller Vioxx? Or with devices like drug-coated stents, which came under a cloud last year after 6 million heart patients had already received them? All roads - and fingers this week - point to the U.S. Food and Drug Administration. From a company's labs to a consumer's...